Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

MRX 5 - MicuRx Pharmaceuticals

Next Previous
Drug Profile

MRX 5 - MicuRx Pharmaceuticals

Alternative Names: MRX 6038; MRX-5 - MicuRx Pharmaceuticals

Latest Information Update: 04 Feb 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator MicuRx Pharmaceuticals
  • Class Antibacterials; Antituberculars; Nonsteroidal anti-inflammatories; Organic boron compounds
  • Mechanism of Action Leucyl-tRNA synthetase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Nontuberculous mycobacterium infections
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Nontuberculous mycobacterium infections
  • Preclinical Gram-negative infections

Most Recent Events

  • 29 Jan 2026 The US FDA approves IND application for MRX 5 in Nontuberculous mycobacterium infections
  • 29 Jan 2026 MicuRx Pharmaceuticals plans a phase IIa trial for Nontuberculous mycobacterium infections in USA
  • 11 Apr 2025 Adverse events data from a preclinical trial in Non-tuberculous mycobacterium infec-tions presented at the 35th Congress of the European Society of Clinical Microbiology and Infectious Disease (ESCMID-2025)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top